miR-181b negatively regulates activation-induced cytidine deaminase in B cells

Activated B cells reshape their primary antibody repertoire after antigen encounter by two molecular mechanisms: somatic hypermutation (SHM) and class switch recombination (CSR). SHM and CSR are initiated by activation-induced cytidine deaminase (AID) through the deamination of cytosine residues on the immunoglobulin loci, which leads to the generation of DNA mutations or double-strand break intermediates. As a bystander effect, endogenous AID levels can also promote the generation of chromosome translocations, suggesting that the fine tuning of AID expression may be critical to restrict B cell lymphomagenesis. To determine whether microRNAs (miRNAs) play a role in the regulation of AID expression, we performed a functional screening of an miRNA library and identified miRNAs that regulate CSR. One such miRNA, miR-181b, impairs CSR when expressed in activated B cells, and results in the down-regulation of AID mRNA and protein levels. We found that the AID 3′ untranslated region contains multiple putative binding sequences for miR-181b and that these sequences can be directly targeted by miR-181b. Overall, our results provide evidence for a new regulatory mechanism that restricts AID activity and can therefore be relevant to prevent B cell malignant transformation.

[1]  Thomas Tuschl,et al.  MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. , 2008, Immunity.

[2]  Michel C Nussenzweig,et al.  MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. , 2008, Immunity.

[3]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[4]  A. Ramiro,et al.  Oncogenic events triggered by AID, the adverse effect of antibody diversification. , 2007, Carcinogenesis.

[5]  T. Ried,et al.  AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements , 2007, The Journal of experimental medicine.

[6]  N. Rajewsky,et al.  MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb , 2007, Cell.

[7]  M. Nussenzweig,et al.  A role for AID in chromosome translocations between c-myc and the IgH variable region , 2007, The Journal of experimental medicine.

[8]  M. Busslinger,et al.  Life beyond cleavage: the case of Ago2 and hematopoiesis. , 2007, Genes & development.

[9]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[10]  N. Kakazu,et al.  Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice , 2007, Proceedings of the National Academy of Sciences.

[11]  C. Croce,et al.  MicroRNA expression and function in cancer. , 2006, Trends in molecular medicine.

[12]  Stefano Volinia,et al.  MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Anton J. Enright,et al.  Zebrafish MiR-430 Promotes Deadenylation and Clearance of Maternal mRNAs , 2006, Science.

[14]  Michel C. Nussenzweig,et al.  Role of genomic instability and p53 in AID-induced c-myc–Igh translocations , 2006, Nature.

[15]  N. Maizels Immunoglobulin gene diversification. , 2005, Annual review of genetics.

[16]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[17]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[18]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[19]  M. Nussenzweig,et al.  AID Is Required for c-myc/IgH Chromosome Translocations In Vivo , 2004, Cell.

[20]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[21]  Vasco M. Barreto,et al.  Somatic Hypermutation Is Limited by CRM1-dependent Nuclear Export of Activation-induced Deaminase , 2004, The Journal of experimental medicine.

[22]  M. Neuberger,et al.  AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification , 2002, Nature.

[23]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[24]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[25]  A. Fischer,et al.  Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2) , 2000, Cell.

[26]  P. Hodgkin,et al.  Switch recombination and germ-line transcription are division-regulated events in B lymphocytes. , 1999, Biochimica et biophysica acta.

[27]  L. Pasqualucci,et al.  AID is required for germinal center–derived lymphomagenesis , 2008, Nature Genetics.

[28]  Vasco M. Barreto,et al.  The role of activation-induced deaminase in antibody diversification and chromosome translocations. , 2007, Advances in immunology.

[29]  Y. Pekarsky,et al.  Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. , 2006, Cancer research.

[30]  J. Stavnezer Antibody class switching. , 1996, Advances in immunology.